MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

Home・Akciju saraksts・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Atvērts

SektorsVeselības aprūpe

1.63 1.87

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.55

Max

1.63

Galvenie mērījumi
By Trading Economics
Ienākumi	-2.8M -16M
Pārdošana	-8.7M 5.5M
Peļņas marža	-282.723
Darbinieki	81
EBITDA	-4.2M -15M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+140.88% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 12. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-12M 640M
Iepriekšējā atvēršanas cena	-0.24
Iepriekšējā slēgšanas cena	1.63

Ziņu noskaņojums

By Acuity

94%

3 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

0.6863 / 0.72 Atbalsts un pretestība

Lexicon Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. apr. 23:17 UTC

Peļņas

Samsung Forecasts Record First-Quarter Operating Profit

2026. g. 6. apr. 23:00 UTC

Karstas akcijas

Stocks to Watch: Health Insurers, Mawson, Owlet

2026. g. 6. apr. 22:13 UTC

Galvenie tirgus virzītāji

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

2026. g. 6. apr. 21:46 UTC

Iegādes, apvienošanās, pārņemšana

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

2026. g. 6. apr. 17:09 UTC

Galvenie tirgus virzītāji

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

2026. g. 6. apr. 16:56 UTC

Galvenie ziņu notikumi

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

2026. g. 6. apr. 14:47 UTC

Galvenie tirgus virzītāji

Stereotaxis Shares Rise on FDA Clearance for Synchrony

2026. g. 7. apr. 00:00 UTC

Galvenie ziņu notikumi

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

2026. g. 6. apr. 23:58 UTC

Tirgus saruna

Galvenie ziņu notikumi

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

2026. g. 6. apr. 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

2026. g. 6. apr. 23:36 UTC

Tirgus saruna

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

2026. g. 6. apr. 23:15 UTC

Tirgus saruna

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

2026. g. 6. apr. 22:52 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 6. apr. 22:52 UTC

Tirgus saruna

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

2026. g. 6. apr. 22:14 UTC

Tirgus saruna

Correction to Live Cattle Futures Article

2026. g. 6. apr. 20:56 UTC

Tirgus saruna

Mexican Private Consumption Fell in January -- Market Talk

2026. g. 6. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 6. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. apr. 19:58 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 6. apr. 19:58 UTC

Tirgus saruna

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

2026. g. 6. apr. 19:11 UTC

Tirgus saruna

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

2026. g. 6. apr. 19:06 UTC

Tirgus saruna

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

2026. g. 6. apr. 19:03 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 6. apr. 19:03 UTC

Tirgus saruna

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

2026. g. 6. apr. 18:36 UTC

Iegādes, apvienošanās, pārņemšana

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026. g. 6. apr. 17:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

2026. g. 6. apr. 17:13 UTC

Iegādes, apvienošanās, pārņemšana

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026. g. 6. apr. 16:33 UTC

Tirgus saruna

Oil Futures Steady as Market Awaits Trump -- Market Talk

2026. g. 6. apr. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. apr. 14:59 UTC

Peļņas

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Salīdzinājums

Cenas izmaiņa

Lexicon Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

140.88% augšup

Prognoze 12 mēnešiem

Vidējais 3.83 USD 140.88%

Augstākais 6 USD

Zemākais 1 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Lexicon Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Lexicon Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.6863 / 0.72Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Noskaņojums

By Acuity

3 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.